Three of the world’s largest pharmaceutical firms are dashing to develop a drug that mimics the effects of an exceedingly rare genetic mutation that causes LDL cholesterol levels to be dramatically low, writes Gina Kolata, of the New York Times.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.
The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.
The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.
An Australian study of personalized medicine has run into problems as it recruits patients.